Publication Summary
Prevention of flares in children with atopic dermatitis with regular use of an emollient containing glycerol and paraffin: a randomized controlled study
Objective
To demonstrate the benefits of using Dexeryl emollient cream in the treatment of mild-to-moderate atopic dermatitis in children, by assessing Dexeryl's ability to prevent flare-ups and reduce the use of corticosteroids.
Study
International, multicenter, randomized, parallel, open-label.
Population
335 children aged 2 to 6 with mild-to-moderate atopic dermatitis, recruited during a flare-up and treated with a strong topical corticosteroid, then randomized once the lesions had cleared (111 treated with Dexeryl, 116 treated with the reference emollient and 108 without emollient treatment).
Dosage
Dexeryl twice a day on the whole body, reference emollient three times a day on affected body areas.
Duration
12 weeks (intermediate assessments after 4 and 8 weeks).
Primary endpoint
Percentage of patients with at least one attack flare-up 12 weeks.
Secondary endpoints
Time to first flare-ups , time to complete remission, number of flare-ups, percentage of patients requiring corticosteroids or immunosuppressants at weeks 4, 8 and 12, corticosteroid consumption.
Tolerance
Good tolerance was observed.
Conclusion
With regular, prolonged application during lulls, DEXERYL Emollient Cream spares eczema attacks1.
DEXERYL Emollient Cream significantly reduces and delays the number of flare-ups compared with untreated patients1. There is a 77.5% reduction in skin dryness at 12 weeks according to parents1. 2 times fewer patients used corticosteroids2.

Publications
1 - Tiplica G.S. et al. The regular use of an emollient improves symptoms of atopic dermatitis in children: a randomised controlled study. JEADV 2018
2- Tiplica G.S. et al. Prevention of flares in children with atopic dermatitis with regular use of an emollient containing glycerol and paraffin: a randomized controlled study. Pediatric Dermatology 2017
Our other publications on this subject
Want to read on?
This access is reserved for professionals, registered on Pierre Fabre For Med.
To access the full content, please register or log in if you already have an account.
